Long-Term Safety And Efficacy Of Add-On Cannabidiol (CBD) Treatment In Patients With Dravet Syndrome In An Open-Label Extension Trial (GWPCARE5)

被引：0
|
作者：
Nabbout, R. [1 ]
Halford, J. [2 ]
Scheffer, I. E. [3 ,4 ]
Sanchez-Carpintero, R. [5 ]
Malawsky, Y. Shiloh [6 ]
Wong, M. [7 ]
Checketts, D. [8 ]
VanLandingham, K. [9 ]
机构：
[1] Necker Enfants Malad Hosp, Paris, France
[2] Med Univ South Carolina, Charleston, SC 29425 USA
[3] Univ Melbourne, Austin Hlth, Melbourne, Vic, Australia
[4] Univ Melbourne, Royal Childrens Hosp, Melbourne, Vic, Australia
[5] Clin Univ Navarra, Madrid, Spain
[6] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[7] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[8] GW Res Ltd, Cambridge, England
[9] Greenwich Biosci Inc, Carlsbad, CA USA
来源：
EPILEPSIA | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P118
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [1] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome in an Open-label Extension Trial (GWPCARE5)
    Patel, Anup
    Gil-Nagel, Antonio
    Chin, Richard
    Mitchell, Wendy
    Perry, M. Scott
    Weinstock, Arie
    Roberts, Claire
    Whyte, Lauren
    VanLandingham, Kevan
    [J]. NEUROLOGY, 2019, 92 (15)
  • [2] Long-Term Safety And Efficacy Of Add-on Cannabidiol (CBD) Treatment in Patients With Lennox-Gastaut Syndrome In An Open-Label Extension Trial (GWPCARE5)
    Chin, R.
    Patel, A.
    Gil-Nagel, A.
    Mitchell, W.
    Perry, M. S.
    Weinstock, A.
    Whyte, L.
    VanLandingham, K.
    [J]. EPILEPSIA, 2019, 60 : 63 - 64
  • [3] Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome in an open-label, Extension Trial
    Halford, Jonathan
    Scheffer, Ingrid
    Nabbout, Rima
    Sanchez-Carpintero, Rocio
    Malawsky, Yael Shiloh
    Wong, Matthew
    Checketts, Daniel
    VanLandingham, Kevan
    [J]. NEUROLOGY, 2019, 92 (15)
  • [4] Maintenance of Long-Term Safety and Efficacy of Cannabidiol Treatment in Dravet Syndrome: Results of the Open-Label Extension Trial (GWPCARE5)
    Devinsky, O.
    Nabbout, R.
    Miller, I.
    Laux, L.
    Zolnowska, M.
    Wright, S.
    Roberts, C.
    [J]. EPILEPSIA, 2018, 59 : S73 - S73
  • [5] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox-Gastaut Syndrome (LGS) in an Open-Label Extension (OLE) Trial (GWPCARE5)
    Perry, M.
    Patel, A.
    Gil-Nagel, A.
    Chin, R.
    Mitchell, W.
    Weinstock, A.
    VanLandingham, K.
    [J]. ANNALS OF NEUROLOGY, 2019, 86 : S76 - S77
  • [6] Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5)
    Laux, L.
    Devinsky, O.
    Miller, I
    Nabbout, R.
    Zolnowska, M.
    Wright, S.
    Roberts, C.
    [J]. ANNALS OF NEUROLOGY, 2018, 84 : S344 - S344
  • [7] Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5)
    Miller, Ian
    Devinsky, Orrin
    Nabbout, Rima
    Laux, Linda
    Zolnowska, Marta
    Wright, Stephen
    Roberts, Claire
    [J]. NEUROLOGY, 2018, 90
  • [8] Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome (DS) in an Open-Label Extension (OLE) Trial
    Shiloh-Malawsky, Y.
    Scheffer, I
    Halford, J.
    Nabbout, R.
    Sanchez-Carpintero, R.
    Wong, M.
    Checketts, D.
    VanLandingham, K.
    [J]. ANNALS OF NEUROLOGY, 2019, 86 : S71 - S72
  • [9] Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome (DS): 3-Year Interim Results of an Open-Label Extension (OLE) Trial (GWPCARE5)
    Halford, Jonathan J.
    Scheffer, Ingrid
    Nabbout, Rima
    Sanchez-Carpintero, Rocio
    Malawky, Yael Shiloh
    Wong, Matthew
    Checketts, Daniel
    Dunayevich, Eduardo
    [J]. NEUROLOGY, 2020, 94 (15)
  • [10] Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome: Results Overall and for Patients Completing 1-3 Years of an Open-Label Extension (GWPCARE5)
    Nabbout, R.
    Sanchez-Carpintero, R.
    Halford, J. J.
    Shiloh-Malawsky, Y.
    Scheirer, I. E.
    Wong, M.
    Checketts, D.
    Dunayevich, E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 435 - 435
12345